The Pilot and Feasibility grant program of the Yale DRC is managed through the Pilot and Feasibility Core. The functions of the Core are to solicit applications from investigators in the Yale School of Medicine and throughout Yale University, to carry out peer review of the applications, and to select meritorious projects for support. Grants are awarded for up to 2 years depending on progress that is made in the first year of funding and plans for the 2rd year. The Core is directed by Kevan Herold, MD who works with an oversight committee that makes final funding selections of grants for support. In the past funding cycle, the Program benefited from additional support available through the CTSA/ARRA funds as well as collaborative support of translational studies with the Yale Clinical Translational Science Award (CTSA). Since the inception of the Yale DRC in 1993, interest and applications to the program has increased - in the past funding cycle, 88 applications were received and 28 were supported. While the majority of applications are received from established investigators, there is a bias towards funding new investigators, many of whom have used the P+F award to obtain preliminary data to apply for external grant support. From the past funding cycle, 11 new external grants were obtained generating over $7M in new research revenue. Studies supported by the P+F program have resulted in more than 40 peer-reviewed publications during the last two funding cycles. The P+F program has also been a mechanism for initiation of new collaborations often between basic and translational scientists. Examples of these collaborations include studies of innate immune pathways that are associated with hepatic insulin resistance and cellular mechanisms of glucose metabolism in adipocytes. In summary the P+F core plays a vital role in attracting new investigators to the diabetes field and recruiting established investigators who are new to diabetes or are developing a new area of diabetes-related research. By effectively utilizing additional sources of revenue, the Core has been able to maintain a high level of funding which has resulted in a high level of productivity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK045735-22
Application #
8730550
Study Section
Special Emphasis Panel (ZDK1-GRB-S)
Project Start
Project End
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
22
Fiscal Year
2014
Total Cost
$327,051
Indirect Cost
$130,624
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Vatner, Daniel F; Goedeke, Leigh; Camporez, Joao-Paulo G et al. (2018) Angptl8 antisense oligonucleotide improves adipose lipid metabolism and prevents diet-induced NAFLD and hepatic insulin resistance in rodents. Diabetologia 61:1435-1446
Keene, Danya E; Guo, Monica; Murillo, Sascha (2018) ""That wasn't really a place to worry about diabetes"": Housing access and diabetes self-management among low-income adults. Soc Sci Med 197:71-77
Hwang, Janice Jin; Parikh, Lisa; Lacadie, Cheryl et al. (2018) Hypoglycemia unawareness in type 1 diabetes suppresses brain responses to hypoglycemia. J Clin Invest 128:1485-1495
Wang, Yongliang; Nasiri, Ali R; Damsky, William E et al. (2018) Uncoupling Hepatic Oxidative Phosphorylation Reduces Tumor Growth in Two Murine Models of Colon Cancer. Cell Rep 24:47-55
RISE Consortium (2018) Impact of Insulin and Metformin Versus Metformin Alone on ?-Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. Diabetes Care 41:1717-1725
Tan, Qiyuan; Tai, Ningwen; Li, Yangyang et al. (2018) Activation-induced cytidine deaminase deficiency accelerates autoimmune diabetes in NOD mice. JCI Insight 3:
Madiraju, Anila K; Qiu, Yang; Perry, Rachel J et al. (2018) Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo. Nat Med 24:1384-1394
Goldberg, Ira J; Reue, Karen; Abumrad, Nada A et al. (2018) Deciphering the Role of Lipid Droplets in Cardiovascular Disease: A Report From the 2017 National Heart, Lung, and Blood Institute Workshop. Circulation 138:305-315
Stamatouli, Angeliki M; Quandt, Zoe; Perdigoto, Ana Luisa et al. (2018) Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes 67:1471-1480
Li, Nina Xiaoyan; Brown, Stacey; Kowalski, Tim et al. (2018) GPR119 Agonism Increases Glucagon Secretion During Insulin-Induced Hypoglycemia. Diabetes 67:1401-1413

Showing the most recent 10 out of 620 publications